insights_auto
Why is ABVX down 2,45%?
Dive Deeperchevron_right
ABVX:EPA
Abivax SA
85,65 €
arrow_downward
-2,45%(-2,15) 1D
1 հոկ, 14:31:34 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
86,90 €
High
87,30 €
Low
84,75 €
Mkt. cap
7,48 մլրդ
Avg. vol.
152,86 հզր
Volume
23,06 հզր
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,53 մլն
No. of employees
98
Open
86,90 €
High
87,30 €
Low
84,75 €
Mkt. cap
7,48 մլրդ
Avg. vol.
152,86 հզր
Volume
23,06 հզր
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,53 մլն
No. of employees
98
News stories
From web sources and news partners
Ideal Investisseur
·
2 ժամ առաջ
Abivax stock drops 12.9% over one month as shorts cover positions
TipRanks
·
16 ժամ առաջ
Abivax to Showcase Extensive Obefazimod Data at UEG Week 2026
Stock Titan
·
16 ժամ առաջ
Researchers will present three-year data on a drug for ulcerative colitis
Timothy Sykes
·
2 օր առաջ
ABVX Stock Draws Bullish Targets As Obefazimod Momentum Builds
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
Founded04 դեկ, 2013 թ.
Headquarters-
Sector-
Websiteabivax.com